Drugs / BGC101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02805023 | Jun 2016 → Jul 2017 overdue | limb ischemia, peripheral arterial disease | BioGenCell Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGC101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02805023 ↗ |
| Modality | Cell therapy | “autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101)” NCT02805023 ↗ |
| Route | Intramuscular | “Intramuscular injections - single treatment session” NCT02805023 ↗ |